Sodium cromoglicate inhalant - Patara Pharma

Drug Profile

Sodium cromoglicate inhalant - Patara Pharma

Alternative Names: Disodium cromoglicate; PA-101; PA-101B

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Patara Pharma
  • Class Antiallergics; Antiasthmatics; Antitussives; Benzopyrans; Chromones; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cough; Pruritus; Systemic mastocytosis

Most Recent Events

  • 07 Sep 2016 Efficacy and adverse events data from a phase II trial in Cough (in patients with idiopathic pulmonary fibrosis) presented at the European Respiratory Society International Congress (ERS-2016)
  • 07 Sep 2016 Patara Pharma plans a phase IIb trial in Cough
  • 01 Feb 2016 Phase-II clinical trials in Pruritus in USA (Inhalation) (NCT02696499)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top